Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Sequencing Pioneer Joins NextCODE

DECEMBER 03, 2014
RDR Staff

One of the leading companies in genome sequencing has added a leading researcher of the same field to their roster.  NextCODE Health has appointed Dr. C Thomas Caskey as senior vice president for medical science and diagnostics. Dr Caskey is professor of molecular and human genetics at Baylor School of Medicine and founder of its Medical Genetics Laboratories and a pioneer in genome sequencing. He will also serve as the founding member and chair of NextCODE’s scientific advisory board.
 
In a statement, Dr Caskey said:

“Sequencing has been solved, and NextCODE’s technology has all of the capabilities needed to bring that data swiftly into widespread clinical use.”
 
“That means a data architecture that can rapidly deliver analysis at scale, accurate diagnosis, and interpretation backed by the best reference sets. Only NextCODE does all that today, and my task is to help get these capabilities into the hands of the institutions and doctors around the world who are using genomics to improve patient outcomes.”

  Jeffrey Gulcher, MD, PhD, president and CSO of NextCODE  added:

“We are thrilled to welcome Tom on board at such an exciting point in the growth of our business and in the medical application of genomics that he has pioneered.”
 
“Tom’s leadership runs from pathbreaking gene discovery through clinical genomics and drug development. His scientific and medical insight will be invaluable across the full range of fields in which our technology promises to advance better healthcare.”

Dr Caskey is board certified in internal medicine, medical genetics and molecular genetics. He is a member of the Institute of Medicine of the National Academy of Sciences and fellow of the Royal Society of Canada. He has served as president of the Human Genome Organization, the American Society of Human Genetics, and the Academy of Medicine, Engineering and Science of Texas. Dr Caskey’s previous appointments include research posts at NIH as well as five years at Merck as senior vice president, research and president of the Merck Genome Research Institute.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.